![Arthur Lieberman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Arthur Lieberman
Geen lopende functies
Loopbaan van Arthur Lieberman
Eerdere bekende functies van Arthur Lieberman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TYRX, Inc.
![]() TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Directeur/Bestuurslid | 26-07-2010 | - |
Opleiding van Arthur Lieberman
Cornell University | Undergraduate Degree |
Brooklyn Law School | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Operationeel
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Director/Board Member | 1 |
Sectoraal
Consumer Services | 3 |
Electronic Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
TYRX, Inc.
![]() TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
- Beurs
- Insiders
- Arthur Lieberman
- Ervaring